Jazz Pharmaceuticals plc
$200.82
▲
0.9%
2026-04-22 10:12:13
www.jazzpharma.com
NMS: JAZZ
Explore Jazz Pharmaceuticals plc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.38 B
Current Price
$200.82
52W High / Low
$207.48 / $97.5
Stock P/E
—
Book Value
$70.3
Dividend Yield
—
ROCE
5.5%
ROE
-8.47%
Face Value
—
EPS
$-5.87
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2,890
Beta
0.23
Debt / Equity
125.67
Current Ratio
1.86
Quick Ratio
1.67
Forward P/E
7.74
Price / Sales
2.8
Enterprise Value
$14.94 B
EV / EBITDA
8.71
EV / Revenue
3.5
Rating
Buy
Target Price
$223.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kyverna Therapeutics, Inc. | $11.25 | — | $600.17 M | — | -65.99% | -64.67% | $13.67 / $1.78 | $3.85 |
| 2. | Bolt Biotherapeutics, Inc. | $5.15 | — | $9.09 M | — | -71.68% | -79.75% | $9.25 / $3.91 | $13.8 |
| 3. | Boundless Bio, Inc. | $1.6 | — | $35.4 M | — | -43.97% | -46.69% | $1.78 / $0.96 | $4.4 |
| 4. | Altimmune, Inc. | $3.56 | — | $463.05 M | — | -35.67% | -50.57% | $7.73 / $2.87 | $2.03 |
| 5. | Skye Bioscience, Inc. | $0.78 | — | $26.15 M | — | -289.25% | -1.27% | $5.75 / $0.57 | $0.6 |
| 6. | Vanda Pharmaceuticals Inc. | $6.99 | — | $417.3 M | — | -43.97% | -50.93% | $9.94 / $3.81 | $5.54 |
| 7. | Spero Therapeutics, Inc. | $2.84 | 19.18 | $164.41 M | — | 11.92% | 16.3% | $3.22 / $0.57 | $1.05 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.2 B | 1.13 B | 1.05 B | 897.84 M | 1.09 B | — |
| Operating Profit | 254.53 M | 100.01 M | 218.97 M | -55.89 M | 190.77 M | — |
| Net Profit | 203.45 M | 251.41 M | -718.47 M | -92.54 M | 191.12 M | — |
| EPS in Rs | 3.3 | 4.08 | -11.67 | -1.5 | 3.1 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.27 B | 4.07 B | 3.83 B | 3.66 B |
| Operating Profit | 517.62 M | 726.63 M | 597.58 M | 512.27 M |
| Net Profit | -356.15 M | 560.12 M | 414.83 M | -224.06 M |
| EPS in Rs | -5.79 | 9.1 | 6.74 | -3.64 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 11.66 B | 12.01 B | 11.39 B | 10.84 B |
| Total Liabilities | 7.34 B | 7.92 B | 7.66 B | 7.75 B |
| Equity | 4.32 B | 4.09 B | 3.74 B | 3.09 B |
| Current Assets | 4.17 B | 4.63 B | 3.44 B | 2.61 B |
| Current Liabilities | 2.24 B | 1.04 B | 1.54 B | 933.19 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.36 B | 1.4 B | 1.09 B | 1.27 B |
| Investing CF | -1.51 B | -508.19 M | -163.06 M | -446.23 M |
| Financing CF | -873.38 M | 20.52 M | -305.25 M | -529.49 M |
| Free CF | 1.15 B | 1.35 B | 1.05 B | 773.78 M |
| Capex | -209.75 M | -48.07 M | -42.96 M | -498.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 6.12% | 4.78% | — | — |
| Earnings Growth % | 35.02% | 285.14% | — | — |
| Profit Margin % | 13.77% | 10.82% | -6.12% | — |
| Operating Margin % | 17.86% | 15.59% | 14% | — |
| Gross Margin % | 89.05% | 88.64% | 85.23% | — |
| EBITDA Margin % | 33.63% | 31.98% | 14.89% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.